Expression of the CD4 and CD8 glycoproteins is a tightly regulated process tied to the maturation of functionally distinct classes of thymocytes. Therefore, understanding of the mechanism of expression of the genes encoding CD4 and CD8 is likely to yield important insight into regulation of the differentiated functions of T cells. Here, we report the identification of a T-cell-specific enhancer in a DNase I-hypersensitive region about 13 kb 5' of the transcription initiation site of the murine CD4 gene. Within the minimal enhancer element, at least three nuclear protein binding sites were identified by DNase I footprint analysis. One site contains the consensus motif for TCF-loLEF-1, a recently identified HMG box transcription factor primarily expressed in.pre-B and T cells. By Southwestern (DNA-protein) blotting and binding competition analyses, the protein binding to this site was found to be indistinguishable from TCF-la/LEF-1. Mutagenesis of this site resulted in loss of factor binding but had a relatively minor effect on enhancer activity. In contrast, mutations in another site, containing two consensus binding motifs for basic helix-loop-helix proteins, abolished factor binding and dramatically reduced enhancer activity. None of the protein binding sites had activity on its own, suggesting that the CD4 enhancer requires the interaction of multiple regulatory sites.
The T-cell surface glycoprotein CD4 is expressed on helper T cells and plays an important signaling role during antigen recognition by binding to a nonpolymorphic region of major histocompatibility complex (MHC) class II molecules (5, 9, 23, 31) . Recent studies suggest that CD4, through its interaction with MHC class II molecules expressed in the thymic microenvironment, also has a critical function in the selection of the T-cell repertoire during thymic ontogeny (7, 25, 33, 38) . In this process, CD4-CD8-pre-T cells differentiate into either CD4+ CD8-or CD4-CD8+ T cells through an intermediate CD4+ CD8+ stage. It is therefore thought that expression of the genes encoding both CD4 and CD8 glycoproteins is positively regulated during the transition from the CD4-CD8-stage to the double-positive stage and then negatively regulated in a mutually exclusive manner during the transition to the single-positive stage. The down-regulation of either CD4 or CD8 gene expression appears to be closely coordinated with the positive selection of T cells bearing appropriate T-cell receptors (TCRs) such that T cells bearing TCRs which recognize MHC class II molecules retain expression of CD4 but shut off CD8, while cells with MHC class I-specific TCRs retain expression of CD8 but shut off CD4 (reviewed in reference 6). The mechanisms governing expression of the CD4 and CD8 genes during these developmental processes remain poorly understood.
Previous studies on T-cell-specific gene expression have focused on genes that are expressed in all mature T lymphocytes, such as genes encoding components of the TCR complex (3, 16, 20) . These studies do not provide a model for differentiation of functionally distinct classes of T lymphocytes. In contrast, analysis of the mechanisms of transcription of the CD4 and CD8 genes is likely to provide additional insight into how specialized MHC-restricted T lymphocytes differentiate. The development of CD4+ and CD8+ cells is * Corresponding author.
accompanied by their differentiation into helper and cytotoxic cells, respectively. The developmental decision to express either CD4 or CD8 is likely to also involve activation of genes that determine the functional phenotype of the T cell. The regulation of CD4 and CD8 transcription may therefore provide a paradigm for the regulation of differentiated functions of T cells.
In earlier studies aimed at identifying transcriptional regulatory elements within the human CD4 gene, a genomic construct containing the coding sequence as well as 3 kb of sequence upstream of the transcription initiation site and 8 kb downstream of the polyadenylation site failed to be expressed in T cells of transgenic mice, suggesting that a T-cell-specific transcriptional enhancer was omitted (46) . To identify such an enhancer element, we have mapped the DNase I-hypersensitive sites surrounding the murine CD4 gene and found that a fragment containing a T-cell-specific hypersensitive site upstream from the transcription initiation site of CD4 enhanced transcription in T cells. We have characterized nuclear protein binding sites in this enhancer element and found that one of the sites interacts with a Tand pre-B-cell-specific nuclear protein that is indistinguishable from TCF-lot/LEF-1, a recently described nuclear protein that also interacts with the enhancer for the gene encoding the TCR a chain (39, 41, 42) . The functional importance of this and the other nuclear protein binding sites was examined and is discussed below.
MATERIALS AND METHODS
Cell culture. All cell lines were grown in RPMI 1640 medium containing 10% fetal calf serum, 50 ,uM 2-mercaptoethanol, and antibiotics.
DNase I-hypersensitive site assay. Nuclei were prepared from 108 cells by the method of Jackson and Chalkley (17) and resuspended in 1 ml of ice-cold buffer (0.25 M sucrose, 10 mM Tris [pH 8 .0], 10 mM MgCl2); 200 ,ul of the suspension was treated with DNase I according to the method of Parslow and Granner (32) . Briefly, DNase I (Worthington) was added to a final concentration of 0 to 12 ,ug/ml. After incubation for 2 min at 37°C, digestion was stopped by addition of 20 ,ul of 10% sodium dodecyl sulfate (SDS) and 4 ,ul of proteinase K (10 mg/ml). Following incubation at 37°C for 2 h, the DNA was purified by phenol-chloroform extraction and ethanol precipitation. DNA (10 p.g) from each sample was digested with an appropriate restriction enzyme, electrophoresed on a 0.8% agarose gel, and transferred to Hybond N. Southern hybridization was performed according to the method of Church and Gilbert (2) .
Isolation of genomic clones. Cosmid clones were isolated from a mouse genomic library provided by Glenn Evans, Salk Institute. Cos 6 was isolated by hybridization to a murine CD4 cDNA probe. Cos 1 and Cos 4 were isolated by hybridization to genomic probes prepared from the two ends of the Cos 6 insert.
Construction of CAT expression vectors. The pCD4CAT vector, in which the chloramphenicol acetyltransferase (CAT) gene is driven by the CD4 promoter, was prepared by replacing the thymidine kinase promoter fragment of pBLCAT2 (24) with the XbaI-to-XhoI fragment (487 bp) of the CD4 promoter region, which contains the transcription initiation site and 70 bp of the untranslated first exon (23a) . Restriction fragments from the CD4 gene were then subcloned into the polylinker at the 5' or 3' end of the pCD4CAT vector. The 339-bp minimal enhancer fragments (BstXI to AvaII) that were mutated in the nuclear protein binding sites were also inserted in the polylinker site at the 5' end of pCD4CAT. To prepare control plasmids, a 4-kb HindIll fragment of the TCR-P enhancer (20) or a simian virus 40 (SV40) enhancer fragment (Hindlll to AccI) from pSV2CAT (10) was inserted to the 5' end of CD4CAT in a 3'-to-5' orientation. The p,CAT vector was prepared by inserting a ClaIto-XhoI fragment from p,CAT106 (provided by R. Myers, University of California, San Francisco), which contains the P-globin promoter (-106 to +26) (29) , the bacterial CAT gene, and the SV40 poly(A) addition site, into ClaI/ XhoI-digested pIC vector (27) , provided by J. Hagman (University of California, San Francisco). The minimal CD4 enhancer fragment or the SV40 enhancer fragment from ppCAT1O6 was inserted into the polylinker at the 3' end of p,BCAT.
Transfection, CAT assay, and luciferase assay. Transfections were performed by using the DEAE-dextran procedure (12) (26) , with minor modifications. Briefly, nuclear proteins (25 ,ug) were separated by SDS-polyacrylamide gel electrophoresis (PAGE) (12% separating gel) and electrotransferred onto a nitrocellulose membrane. The membrane was washed three times for 1 h each with renaturation buffer (10 mM Tris-HCl [pH 7.5], 150 mM NaCl, 10 mM DTT, 2.5% Nonidet P-40, 10% glycerol, 5% nonfat dry milk). After brief washing in the binding buffer (10 mM Tris-HCl [pH 7.5], 40 mM NaCl, 1 mM DTT, 1 mM EDTA, 5 mM MgCl2, 8% glycerol, 0.125% nonfat dry milk), the membrane was incubated in the binding buffer with 50 ,ug of poly(dI-dC)-poly(dI-dC), 5 ,g of salmon sperm DNA, and 5 x 106 cpm of 32P-labeled oligonucleotide probe per ml. After overnight incubation with agitation at room temperature, the membrane was washed four times (30 min each) in 10 mM Tris-HCl (pH 7.5)-50 mM NaCl.
Site-directed mutagenesis. The minimal enhancer fragment was inserted into the polylinker site of pBS KS(+) vector, and single-stranded DNA was prepared by infection of the bacteria with helper phage. Mutants were produced by using an oligonucleotide-mediated, gapped heteroduplex mutagenesis protocol according to the manual of the Muta-Gene in vitro mutagenesis kit (Bio-Rad). All mutants were confirmed by dideoxy-DNA sequence analysis with commercially available Sequenase reagents (U.S. Biochemical Corp., Cleveland, Ohio).
Nucleotide sequence accession number. The nucleotide sequence reported in this paper has been assigned the GenBank accession number M75688. (Fig. 1A) . HS (hypersensitive site)1 and HS2 were located more than 10 kb upstream from the transcription initiation site, while HS3 was about 100 bp upstream and thus appears to correspond to the CD4 promoter. HS4 was detected in the first intron, and HS5 through HS8 were detected downstream from the last exon.
We further studied the tissue specificity of the upstream DNase I-hypersensitive sites, HS1 and HS2. These sites were detected in all T-cell lines tested, including CD4+ CD8+, CD4+ CD8-, and CD4-CD8+ cells (Fig. 1B) .
However, they were absent from the B-cell line M12. HS1 and HS2 therefore represent T-cell-specific DNase I-hypersensitive sites.
The DNA fragment from the HS2 site has T-cell-specific enhancer activity. We examined restriction fragments containing the DNase I-hypersensitive sites and several other fragments from genomic clones covering about 80 kb of the murine CD4 locus for enhancer activity (Fig. 1A) . These fragments were subcloned upstream of the CD4 promoter fused to the bacterial CAT reporter gene, and the plasmids were transfected into a CD4+ subclone of the human T-cell tumor cell line Jurkat. The only fragment found to augment CAT activity in comparison with the CD4 promoter alone was a 0.8-kb fragment (NdeI to HinflI) containing the HS2 site ( Fig. 2 and data not shown). This sequence functions in both orientations relative to the promoter as well as both (Fig. 2) . This T-cell-specific activity seems not to be a property of the CD4 promoter, since the promoter itself works well in non-T-cell lines in combination with the SV40 enhancer (Fig. 2) . The TCR ,-chain enhancer was used as a T-cell-specific positive control.
To delimit the region containing the T-cell-specific enhancer activity, several restriction fragments were prepared from the 0.8-kb NdeIlHinflI fragment and tested for activity in T-and non-T-cell lines (Fig. 2) . A 339-bp fragment (BstXI to AvaIl) was at least as effective as the 0.8-kb fragment in all T cells tested. A 181-bp PvuII fragment functioned as well as the 0.8-kb fragment in Jurkat cells but had significantly reduced activity in 1200M cells and in another murine T-cell line, SL3B (data not shown). Other smaller restriction fragments had much less activity than the 339-bp fragment in all T-cell lines tested. The 339-bp fragment therefore appears to contain the minimal enhancer, as further truncation results in loss of activity in at least some T-cell lines.
Confirmation that T-cell specificity was dictated by the enhancer element rather than by the CD4 promoter was obtained by testing the activity of the enhancer on heterologous promoters. The 339-bp fragment was subcloned into plasmid ppCAT downstream from a CAT reporter gene driven by the ,-globin promoter (-106 to +26). Following transfection into Jurkat cells, the 339-bp fragment, in either orientation, augmented CAT gene expression from the ,-globin promoter 7-to 28-fold (Table 1) . While this activity was lower than that observed with the CD4 promoter, it was detected only in the transfected T-cell line, not in transfected M12 B cells. Plasmid p,CAT containing an SV40 enhancer functioned well in B cells, demonstrating that the ,-globin promoter is active in these cells. Similar results were obtained when the enhancer was coupled to other heterologous promoters, including the SV40 early region promoter and the murine CD2 promoter (data not shown). However, enhancement of transcription from heterologous promoters was always considerably less efficient (or absent, as in the case of Sequence of the minimal enhancer element and identification of protein binding sites by DNase I footprinting. DNase I footprint analysis using crude T-and B-cell nuclear extracts was performed to identify specific nuclear protein binding sites in the minimal enhancer element (Fig. 3A) . Three discrete regions (CD4-1, CD4-2, and CD4-3) were reproducibly protected from DNase I digestion on both strands by the T-cell nuclear extract. In contrast, the B-cell extract protected the CD4-1 and CD4-3 regions but not the CD4-2 site, suggesting that CD4-2 interacts with a T-cell-specific protein. DNA sequence analysis of the 339-bp enhancer element (Fig. 3B) revealed that the CD4-2 site contains a sequence closely related to sequences of nuclear protein binding sites within enhancers of several other T-cell-specific genes (Fig.  3C ). All of these sequences share the consensus motif 5'-CANAG-3', to which the recently identified T-cell-specific nuclear factor TCF-lot/LEF-1 has been shown to bind (42) .
The CD4-1 and CD4-3 sites were found to contain consensus binding sites for basic helix-loop-helix (bHLH) proteins, 5'-CANNTG-3' (43); a single bHLH binding site motif was present in CD4-1 and two, with incomplete dyad symmetry (CAGGTGTCAGCTG), were present in CD4-3. In addition, partial homologies to AP-2 and AP-1 binding site motifs were detected in CD4-1 and CD4-3, respectively (Fig. 3C) . Several other regions within the minimal enhancer fragment that were not protected in the DNase I footprinting analysis were also found to be homologous or identical to nuclear protein binding sites found in other T-cell-specific enhancers (Fig.   3C ).
Characterization of nuclear proteins binding to the minimal CD4 enhancer by EMSA. To further characterize individual protein binding sites within the minimal CD4 enhancer, EMSA was performed with oligonucleotides corresponding to binding sites CD4-1, CD4-2, and CD4-3. Labeled synthetic oligonucleotides were incubated with nuclear extract from the T-cell line SL3B and subjected to EMSA. Specific protein-DNA interactions were identified by the ability to block complex formation with competing wild-type oligonucleotides but not with mutant oligonucleotides or salmon sperm DNA (Fig. 4) . Mutant oligonucleotides used for competition were chosen based on the bHLH motifs for the CD4-1 and CD4-3 sites and on the TCF-l(x/LEF-1 motif for the CD4-2 site (Fig. 4A) .
Interestingly, the formation of specific complexes with labeled CD4-1 oligonucleotide was blocked not only by excess unlabeled wild-type CD4-1 but also by wild-type CD4-3 oligonucleotide (Fig. 4B) . Similarly, wild-type CD4-1 oligonucleotide competed with labeled CD4-3 oligonucleotide for the formation of two of three nuclear protein complexes (Fig. 4C) . However, mutant CD4-1 and CD4-3 oligonucleotides failed to compete with either labeled CD4-1 or CD4-3 oligonucleotide (Fig. 4B and C) . These results suggest that a common nuclear protein(s) interacts with both the CD4-1 and CD4-3 sites in the enhancer element. Because both the CD4-1 and CD4-3 sites have bHLH binding motifs, it is likely that one or more common bHLH protein binds to both sites. The fastest-migrating complex observed with CD4-3 is probably identical to that observed with CD4-1. The ability of CD4-1 to block the formation of some, but not all, nuclear protein complexes with the CD4-3 oligonucleotide may be due to different affinities of these oligonucleotides for the same protein or to the ability of the duplicated bHLH motif in CD4-3 to bind additional proteins. Since the CD4-2 site contains a consensus motif for binding the nuclear factor TCF-l/LEF-1, we assayed CD4-2 oligonucleotides with mutations within or outside this motif for their ability to bind the nuclear factor. Substitution of base pairs in the TCF-la/LEF-1 motif abolished the ability of the oligonucleotide to compete with labeled CD4-2 oligonucleotide in EMSA (Fig. 4D, mutants MT1 and MT4) . In contrast, the change of bases outside of the motif did not significantly affect the binding affinity in the competition assay (Fig. 4D, mutants MT2 and MT3) . These results are consistent with an interaction between the CD4-2 binding protein and the TCF-la/LEF-1 motif. Another series of competition experiments was carried out by using a labeled oligonucleotide, corresponding to the Ta2 site of the TCR-a enhancer (14) , previously shown to interact with TCF-la/ LEF-1 (42) (Fig. 4E) . The nuclear protein-DNA complex formed with the Ta2 oligonucleotide comigrated with that formed with the CD4-2 oligonucleotide, and its formation was blocked completely by excess cold wild-type CD4-2 oligonucleotide but not by excess mutant CD4-2 oligonucleotide (MT1), which also does not compete with labeled CD4-2 oligonucleotide (Fig. 4E) . It is noteworthy that substitution of TAT for AAA in the TCF-la/LEF-1 motif of the CD4-2 region (mutant MT4) completely abolished binding of the nuclear factor (Fig. 4D) ; the same mutation in the Ta2 site was previously shown to abolish binding of TCF-laI LEF-1 (42) . These results indicate that the same nuclear protein interacts with both CD4-2 and Ta2 oligonucleotides and are consistent with TCF-la/LEF-1 binding to both sites.
Cell type specificity of the enhancer-binding proteins. To examine the cell type specificity of the binding proteins, we compared nuclear extracts from a variety of T-and non-Tcell lines in EMSA, using the three binding-site oligonucleotides (Fig. 5) . Nuclear proteins binding to the CD4-1 and CD4-3 sites were detected in T cells, B cells, and nonlymphoid HeLa cells, suggesting that they are ubiquitously expressed ( Fig. 5A and C) . However, subtle differences in mobility were detected with extracts from various lymphoid and nonlymphoid cells (HeLa versus Jurkat cells in Fig. 5A and C and unpublished results), raising the possibility that distinct factors bind to these sites in different cell types. Consistent with the footprint analysis, CD4-2 binding activity was detected in all T-cell lines but not in mature B-cell lines or nonlymphoid cell lines (Fig. SB) . Unexpectedly, this protein was also present in all pre-B-cell lines tested. Therefore, the CD4-2-binding protein appears to be specifically expressed in T and pre-B cells. This pattern of expression corresponds to that observed for the lymphoid-specific nuclear factor TCF-la/LEF-1 (39), providing further evidence that this protein binds to the CD4-2 site of the enhancer.
The CD4-2-binding protein is indistinguishable from TCFla/LEF-1. Several of the results presented above support the notion that the CD4-2-binding factor is TCF-laILEF-1: binding of nuclear protein to the CD4-2 site requires an intact TCF-la/LEF-1 motif; CD4-2 oligonucleotide competes for factor binding to the Ta2 site, which is known to bind TCF-laILEF-1; and the CD4-2-binding factor and TCF-la/ LEF-1 transcripts have similar cellular distribution. In addition, EMSA and methylation interference assays performed with in vitro-translated TCF-lo/LEF-1 protein demonstrated specific binding to the CD4-2 site of the enhancer (1) .
To further test the hypoth-sis that TCF-la/LEF-1 binds to the CD4-2 site, we performed Southwestern blotting analysis to identify nuclear proteins that bind specifically to this sequence. A labeled oligonucleotide probe corresponding to the CD4-2 site specifically bound to a protein doublet migrating at 53 to 57 kDa on SDS-PAGE (Fig. 6A) . Mutant Cell type specificity of DNA-protein complexes formed with CD4 enhancer elements. Extracts from a variety of T-and non-T-cell lines were tested for binding activity with end-labeled oligonucleotide probes corresponding to the CD4-1 (A), CD4-2 (B), and CD4-3 (C) sites. The specific complexes that have been characterized by competition with unlabeled oligonucleotides are indicated by arrows. Binding conditions differ from those used for Fig. 4B and C (see Materials and Methods); hence, in panel C, only complexes corresponding to the faster-migrating species in Fig. 4C are indicated. In separate experiments, using conditions identical to those used for Fig. 4B and C, the cellular distribution of all specific complexes formed with CD4-1 and CD4-3 oligonucleotides was similar to that shown in this figure (data not shown). SL3B is a CD4-CD8-murine T-cell line; C6VLB is a CD4+ CD8-murine T-cell line; 1200M is a CD4-CD8+ murine T-cell line; 10105 is a CD4+ CD8+ murine T-cell line; Jurkat is a CD4+ CD8-human T-cell line; 70Z/3, 38B9, and PD36 are murine pre-B-cell lines; M12 is a murine mature B-cell line; SP-2 is a murine myeloma; NIH 3T3 is a murine fibroblast line; HeLa is a human cervical carcinoma cell line.
oligonucleotide probes MT1 and MT4, whose binding was abolished in EMSA (Fig. 4D) , could not detect the same protein, while MT2, which retained binding, detected the same doublet. To examine the tissue specificity of this protein, nuclear extracts from a variety of T-cell and non-Tcell lines were similarly probed (Fig. 6B) . A doublet at approximately 53 to 57 kDa was detected in all T-cell lines and pre-B-cell lines tested (Fig. 6B) . In contrast, this protein was absent from mature B cells and nonlymphoid cell lines. The cell type specificity of this protein is therefore identical to that of the nuclear protein-DNA complex observed in EMSA. To determine whether the protein binding to the CD4-2 site is related to that binding to the TCF-la/LEF-1 site in the TCR-ot enhancer, Southwestern blotting of T-and non-T-cell extracts was carried out with probes corresponding to the CD4-2 and Ta2 sites. Nitrocellulose membranes, A,. B onto which had been blotted duplicate samples separated by SDS-PAGE, were incubated with a labeled CD4-2 or Ta2 oligonucleotide probe (Fig. 6C) . The T-cell-specific protein identified by the Tax2 probe migrated at 53 to 57 kDa, the same size as that previously reported for TCF-la/LEF-1 (42) . Moreover, both the CD4-2 and Ta2 probes detected the protein doublet in this molecular size range (Fig. 6C) . Taken together, these results strongly suggest that the same nuclear factor, TCF-1odLEF-1, interacts with both CD4-2 and Tai2 sites through their shared sequence motif.
Functional analysis of individual protein binding sites within the CD4 enhancer. To determine the role of each of the three nuclear protein binding sites in transcriptional enhancement, we next examined the effect of mutations in these regions on enhancer activity (Fig. 7) . The binding activity of each mutant had been previously determined by EMSA; CD4-1 MT, CD4-2 MT1, CD4-2 MT4, and CD4-3 MT were shown to be defective in binding their respective nuclear proteins, whereas CD4-2 MT2 retained binding activity (Fig. 4A to D) . These mutations, either singly or in combinations, were introduced into the 339-bp minimal enhancer fragment and tested for their effects on enhancement of CAT expression directed by the CD4 promoter. Mutations resulting in loss of nuclear protein binding to CD4-1 and CD4-2 resulted in only a moderate decrease in enhancer activity (two-to fourfold) in both Jurkat and 1200M cell lines. Mutations in both the CD4-1 and CD4-2 binding sites had no greater effect on activity than did mutation of either element alone. In contrast, mutation of the CD4-3 site resulted in a greater than 90% reduction of enhancer activity in both cell lines, with complete loss of activity in 1200M. All combinations of mutations that included a mutant CD4-3 site resulted in loss of activity. Similar results were obtained when these mutant enhancer elements were tested in conjunction with the ,-globin promoter fused to the CAT reporter gene (data not shown). Significantly, none of the mutant enhancer fragments functioned in M12 B cells (data not shown). Since mutations resulting in loss of protein binding to the TCF-la/ LEF-1 motif in CD4-2 retain the T-cell specificity of the enhancer fragment, it is likely that additional factors are involved in mediating the T-cell-specific activity of this enhancer.
DISCUSSION
In this study, we have identified and characterized a T-cell-specific transcriptional enhancer element that is closely linked to the murine CD4 gene. This element displays T-cell-specific enhancing activity when coupled to several promoters but functions best in conjunction with the CD4 promoter. Restriction fragments containing this element were the only ones found to have enhancer activity within an 80-kb span of the murine CD4 locus. Previous experiments showed that a CD4 gene construct containing only 3 kb upstream of the transcriptional start site, and thus lacking this element, was not expressed in transgenic mice (46) . Taken together, these findings strongly suggest that the enhancer element described here has a major role in the regulation of CD4 gene expression.
Several other T-cell-specific genes, including those encoding CD2, CD3-e, CD3-8, TCR-a, TCR-P, and TCR-y, have closely linked T-cell-specific enhancer elements downstream from the polyadenylation site (3, 8, 16, 19-21, 28, 36) . Although we identified several DNase I-hypersensitive sites downstream of the CD4 gene, we could not detect enhancer activity within 20 kb of DNA in this region. Instead, we detected significant enhancer activity in a region about 13 kb upstream of the transcriptional start site of the CD4 gene, in a location corresponding to a T-cell-specific DNase I-hypersensitive site, HS2. This enhancer was localized to a 339-bp fragment that functioned in all T cells tested but not in a mature B-cell line or in fibroblasts. The enhancer was functional in CD4+ T-cell lines as well as in the CD4-CD8+ T-cell line, 1200M, in which mRNA for endogenous CD4 was not detectable (data not shown). This result was consistent with the presence of HS2 in 1200M cells (Fig. 1B) .
Three nuclear protein binding sites, CD4-1, CD4-2, and CD4-3, were identified in the minimal enhancer element. The CD4-2 site contains a consensus motif, 5'-CANAG-3', for interaction with the recently identified T-cell-specific nuclear factor TCF-la/LEF-1 (42) . By gel shift competition assays and Southwestern blotting analysis, we have concluded that the 53-to 57-kDa nuclear proteins that bind to the CD4-2 site are indistinguishable from TCF-la/LEF-1. Our results also demonstrated that the CD4-2-binding protein was expressed in T-and pre-B-cell lines but not in more mature B-cell lines. This pattern of expression corresponds to that observed for TCF-la/LEF-1 (39) . The cDNAs for LEF-1 and TCF-lot were recently characterized and found to encode mouse and human homologs of the same protein, a new member of the HMG box family of DNA-binding proteins (39, 41) . The HMG box of TCF-la/LEF-1 has been shown to be sufficient for binding to the Ta2 site of the TCR-a enhancer (39, 41) . Recombinant TCF-1a/LEF-1 was also shown to bind to the CD4-2 element (1). Taken together, these observations provide strong evidence that TCF-la/LEF-1 is the lineagespecific factor binding at the CD4-2 site.
A second T-cell-specific HMG family member, named TCF-1, has been recently shown to bind to the core motif 5'-AACAAAG-3' within the CD3-e enhancer and to transactivate through this enhancer (40) . TCF-1 and TCF-laI LEF-1 have very closely related HMG box sequences but are otherwise dissimilar. While they both bind to DNA sequences that contain the motif 5'-CANAG-3', it is not yet known whether they have distinct flanking sequence requirements. We have failed to clearly detect the smaller TCF-1 protein on Southwestern blots and, presumably, on EMSA. While this may be due to a lower affinity of TCF-1 than of TCF-la/LEF-1 for the CD4-2 site, it may also reflect a requirement for special conditions in the binding assays. It therefore remains to be determined whether TCF-1, like TCF-la/LEF-1, binds to the CD4-2 site within the CD4 enhancer.
Curiously, site-directed mutagenesis of the CD4-2 site, resulting in loss of binding of the T-cell-specific 53-to 57-kDa protein, had only a slight effect on enhancer function in T-cell lines. Likewise, mutation of the single bHLH binding motif within the CD4-1 sit-, to which a ubiquitous factor appears to bind, had little effect on enhancer activity. In contrast, a mutation within the CD4-3 site, which affects the two tandemly positioned bHLH binding motifs and abrogates binding of ubiquitous nuclear factors, resulted in complete loss of activity, strongly suggesting a key role for VOL . 1 l, 1991 2 
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SAWADA AND LITTMAN the CD4-3 site in the enhancer function. Dispensing with the CD4-2 binding site did not affect the T-cell specificity of the enhancer, suggesting that factors other than TCF-la/LEF-1 can confer T-cell specificity upon the 339-bp enhancer. It is possible, for example, that both ubiquitous and T-cellspecific bHLH proteins bind to the CD4-3 element; such different factors may be difficult to distinguish by gel shift assays. Alternatively, T-cell-specific factors binding to a second putative TCF-lo/LEF-1 binding site in the CD4 enhancer (Fig. 3C) , binding that was not detected by footprinting, may permit T-cell-specific function even in the absence of nuclear protein binding to the CD4-2 site. If this latter hypothesis is correct, expression of TCF-lo/LEF-1 may be sufficient for effective transactivation of CD4 enhancer-reporter constructs in non-T cells.
Previous studies with the human TCR-a enhancer showed that removal of the Ta2 element, which contains the TCFla/LEF-1 binding motif, had little effect on the activity of the full enhancer (14) . Other protein binding sites in the Ta3 and Ta4 elements of the enhancer were found to compensate for the deletion of the Ta2 site. Even though EMSA analysis did not reveal any T-cell-specific factors other than that binding to the TCF-lo/LEF-1 motif, a second T-cell-specific factor, GATA-3, was recently shown to bind to Ta3 (15) . This result highlights the likelihood that additional T-cell-specific factors also bind to the CD4 enhancer.
Transfection experiments with deletion mutants of the CD4 enhancer fragment demonstrated that a 193-bp fragment containing the CD4-3 site but not the CD4-1 and CD4-2 sites had much less enhancer activity than did the minimal 339-bp enhancer fragment. Therefore, it is likely that interaction of multiple regulatory sites in the minimal enhancer is necessary for optimal enhancer activity. This requirement resembles that observed with the Tal/Ta2 segment of the TCR-a enhancer. Function of this segment appears to require the interaction of proteins binding to closely linked CREB, TCF-lo/LEF-1, and ets-1 motifs; as observed with the CD4 enhancer, mutations that resulted in loss of nuclear protein binding to the TCF-la/LEF-1 motif in Ta2 had only a partial effect on expression in T cells (39, 42) . However, mutation of the ets-1 motif in Tat2 resulted in complete loss of activity (13) , as did mutations in the CD4-3 site of the CD4 enhancer. TCF-laILEF-1 may therefore interact with closely bound critical DNA binding factors in both the CD4 and TCR-a enhancers.
In the thymus, expression of the CD4 and CD8 glycoproteins is positively regulated at early stages and negatively regulated at later stages of development. Since the level of cell surface CD4 and CD8 reflects the steady-state level of mRNA, it is believed that expression of these molecules is regulated at the transcriptional level. Signal transduction through the TCR and either CD4 or CD8, which appear to function as signal-transducing coreceptors (9, 18) , may down-regulate expression of the locus whose product is not engaged in signaling. In this study, we have investigated the properties of a CD4 enhancer that up-regulates transcription in all T-cell lines tested, including a CD4-thymoma, 1200M. Activity of the enhancer in 1200M cells may reflect an abnormal property of this cell line, and the enhancer still may, in an appropriate developmental context, be properly down-regulated. Alternatively, the endogenous CD4 promoter and/or enhancer may be inactivated by a negative regulator, such as a silencer element, which is missing in the transfected CAT construct. The latter possibility is especially attractive, as a silencer element outside of the TCR-a enhancer was earlier shown to block enhancer function in TCR--yb T cells and non-T cells but not in TCR-ota T cells (45) . Additional cis-acting elements may therefore be required to detect T-cell subset-specific expression in transfected cells. However, we have been unable to detect silencing activity in 1200M cells upon transfection of CAT constructs into which had been inserted fragments containing several of the other DNase I-hypersensitive sites around the CD4 gene.
A complete understanding of CD4 expression will require studies of the mechanism of negative regulation during selection of CD8+ cells and of the ability of cis-acting elements to mediate temporal signals in thymic differentiation. Such an understanding will require the analysis of the function of cis-acting sequences in transgenic mice. The characterization of this candidate CD4 enhancer will significantly facilitate such future studies.
